Dr. Jan Petracek
Dr. Jan Petracek is an expert in pharmacovigilance and risk management.
He is the former Head of Risk Management Section at the European Medicines Agency, and the former Head of Pharmacovigilance, Strategy and Development at the State Institute for Drug Control in the Czech Republic.
He has unique education in Quality and Safety in Healthcare (MSc) from the Imperial College London, and trained as a physician at Charles University in Prague (MD). He has written and/or contributed to many national and international guidelines, including ICH E2F, EMA Guideline on Safety and Efficacy Follow-up – Risk Management of Advanced Therapies, and parts of Volume 9A.
Jan is a Board Member and President of PrimeVigilance since November 2016 and leads both PharmInvent and PrimeVigilance as CEO since April 2017.